MiR-19a-3p Functions As an Oncogene by Regulating FBXO32 Expression in Multiple Myeloma

Overview

Journal Balkan Med J

Publisher Galenos Publishing House

Specialty General Medicine

Date 2020 Sep 25

PMID 32975519

Citations 4

Authors

Ying Li

Song Gao

Wenjing Xue

Yanna Ma

Yuesheng Meng

Dawei Zhang

Affiliations

Soon will be listed here.

Abstract

Background: Multiple myeloma remains a virtually incurable hematologic malignancy, which is featured with the aberrant growth of malignant plasma cells.

Aims: To elucidate the functions of miR-19a-3p in multiple myeloma.

Study Design: Cell study.

Methods: Cell counting kit-8 assay was performed to detect cell viability, and flow cytometry was conducted to detect cell apoptosis. Bioinformatics analysis predicted miR-19a-3p-associated biological function, pathway, core regulatory network, and target genes. Luciferase reporter assay verified the target sequence of miR-19a-3p regulating FBXO32.

Results: miR-19a-3p is upregulated in multiple myeloma cells (p<0.01) and patients with multiple myeloma (p<0.001). Overexpressed miR-19a-3p significantly increased cell viability (p<0.05) and inhibited cell apoptosis (p<0.01). FBXO32 is a target gene of miR-19a-3p (p<0.01). Moreover, FBXO32 is downregulated in MM, and it significantly decreased cell viability (p<0.05) and promoted cell apoptosis (p<0.01). FBXO32 significantly rescued the influence of miR-19a-3p-inhibiting cell apoptosis (p<0.05).

Conclusion: miR-19a-3p promoted cell proliferation and inhibited cell apoptosis by degrading the target FBXO32 mRNA in multiple myeloma.

Citing Articles

Decoding the interaction between miR-19a and CBX7 focusing on the implications for tumor suppression in cancer therapy.

Zabeti Touchaei A, Vahidi S, Samadani A Med Oncol. 2023; 41(1):21.

PMID: 38112798 DOI: 10.1007/s12032-023-02251-y.

Long non-coding RNA KCNQ10T1/miR-19a-3p/SMAD5 axis promotes osteogenic differentiation of mouse bone mesenchymal stem cells.

Lin H, Nie L, Lu G, Wu H, Xu T J Orthop Surg Res. 2023; 18(1):929.

PMID: 38057885 PMC: 10698940. DOI: 10.1186/s13018-023-04425-w.

Promotive Effect of FBXO32 on the Odontoblastic Differentiation of Human Dental Pulp Stem Cells.

Xu K, Liu Q, Huang W, Chu Y, Fan W, Liu J Int J Mol Sci. 2023; 24(9).

PMID: 37175415 PMC: 10178205. DOI: 10.3390/ijms24097708.

The microRNA miR-19a-3p suppresses cell growth, migration, and invasion in multiple myeloma via the Wnt/β-catenin pathway.

Wei Z, Wang W, Li Q, Du L, He X Transl Cancer Res. 2022; 10(2):1053-1064.

PMID: 35116432 PMC: 8798127. DOI: 10.21037/tcr-20-3490.

References

Vicente-Duenas C, Romero-Camarero I, Garcia-Criado F, Cobaleda C, Sanchez-Garcia I . The cellular architecture of multiple myeloma. Cell Cycle. 2012; 11(20):3715-7. PMC: 3495807. DOI: 10.4161/cc.22178. View

Gomes M, Lecker S, Jagoe R, Navon A, GOLDBERG A . Atrogin-1, a muscle-specific F-box protein highly expressed during muscle atrophy. Proc Natl Acad Sci U S A. 2001; 98(25):14440-5. PMC: 64700. DOI: 10.1073/pnas.251541198. View

Hao M, Zang M, Wendlandt E, Xu Y, An G, Gong D . Low serum miR-19a expression as a novel poor prognostic indicator in multiple myeloma. Int J Cancer. 2014; 136(8):1835-44. PMC: 4382914. DOI: 10.1002/ijc.29199. View

Guo W, Zhang M, Guo Y, Shen S, Guo X, Dong Z . FBXO32, a new TGF-β/Smad signaling pathway target gene, is epigenetically inactivated in gastric cardia adenocarcinoma. Neoplasma. 2015; 62(4):646-57. DOI: 10.4149/neo_2015_078. View

Zhong X, Coukos G, Zhang L . miRNAs in human cancer. Methods Mol Biol. 2011; 822:295-306. PMC: 4076826. DOI: 10.1007/978-1-61779-427-8_21. View

Kyle R, Rajkumar S . Multiple myeloma. Blood. 2008; 111(6):2962-72. PMC: 2265446. DOI: 10.1182/blood-2007-10-078022. View

Rushworth S, Murray M, Barrera L, Heasman S, Zaitseva L, MacEwan D . Understanding the role of miRNA in regulating NF-κB in blood cancer. Am J Cancer Res. 2011; 2(1):65-74. PMC: 3236572. View

Yang Y, Shi J, Tolomelli G, Xu H, Xia J, Wang H . RARα2 expression confers myeloma stem cell features. Blood. 2013; 122(8):1437-47. PMC: 3750340. DOI: 10.1182/blood-2013-02-482919. View

Lv H, Wu X, Ma G, Sun L, Meng J, Song X . An integrated bioinformatical analysis of miR-19a target genes in multiple myeloma. Exp Ther Med. 2017; 14(5):4711-4720. PMC: 5704339. DOI: 10.3892/etm.2017.5173. View

10.

Zhang X, Chen Y, Zhao P, Zang L, Zhang Z, Wang X . MicroRNA-19a functions as an oncogene by regulating PTEN/AKT/pAKT pathway in myeloma. Leuk Lymphoma. 2016; 58(4):932-940. DOI: 10.1080/10428194.2016.1213827. View

11.

Szklarczyk D, Gable A, Lyon D, Junge A, Wyder S, Huerta-Cepas J . STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2018; 47(D1):D607-D613. PMC: 6323986. DOI: 10.1093/nar/gky1131. View

12.

Yang J, Zhang Z, Chen C, Liu Y, Si Q, Chuang T . MicroRNA-19a-3p inhibits breast cancer progression and metastasis by inducing macrophage polarization through downregulated expression of Fra-1 proto-oncogene. Oncogene. 2013; 33(23):3014-23. DOI: 10.1038/onc.2013.258. View

13.

Kuleshov M, Jones M, Rouillard A, Fernandez N, Duan Q, Wang Z . Enrichr: a comprehensive gene set enrichment analysis web server 2016 update. Nucleic Acids Res. 2016; 44(W1):W90-7. PMC: 4987924. DOI: 10.1093/nar/gkw377. View

14.

Mei Z, Zhang D, Hu B, Wang J, Shen X, Xiao W . FBXO32 Targets c-Myc for Proteasomal Degradation and Inhibits c-Myc Activity. J Biol Chem. 2015; 290(26):16202-14. PMC: 4481220. DOI: 10.1074/jbc.M115.645978. View

15.

Paraskevopoulou M, Georgakilas G, Kostoulas N, Vlachos I, Vergoulis T, Reczko M . DIANA-microT web server v5.0: service integration into miRNA functional analysis workflows. Nucleic Acids Res. 2013; 41(Web Server issue):W169-73. PMC: 3692048. DOI: 10.1093/nar/gkt393. View

16.

Wang J, Zhou W, Cheng S, Liu B, Liu F, Song J . Downregulation of Sprouty homolog 2 by microRNA-21 inhibits proliferation, metastasis and invasion, however promotes the apoptosis of multiple myeloma cells. Mol Med Rep. 2015; 12(2):1810-6. PMC: 4464399. DOI: 10.3892/mmr.2015.3567. View

17.

Baker S, Ali I, Silins I, Pyysalo S, Guo Y, Hogberg J . Cancer Hallmarks Analytics Tool (CHAT): a text mining approach to organize and evaluate scientific literature on cancer. Bioinformatics. 2017; 33(24):3973-3981. PMC: 5860084. DOI: 10.1093/bioinformatics/btx454. View

18.

Shi Y, Jin Y . MicroRNA in cell differentiation and development. Sci China C Life Sci. 2009; 52(3):205-11. DOI: 10.1007/s11427-009-0040-5. View

19.

Zhou H, Liu Y, Zhu R, Ding F, Wan Y, Li Y . FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation. Oncogene. 2017; 36(23):3312-3321. PMC: 5926769. DOI: 10.1038/onc.2016.479. View

20.

Guo W, Zhang M, Shen S, Guo Y, Kuang G, Yang Z . Aberrant methylation and decreased expression of the TGF-β/Smad target gene FBXO32 in esophageal squamous cell carcinoma. Cancer. 2014; 120(16):2412-23. DOI: 10.1002/cncr.28764. View